ALISO VIEJO, Calif.--(BUSINESS WIRE)--Ambry Genetics, a prominent leader in clinical genomic testing and a subsidiary of REALM IDx, Inc., unveiled at the American Society of Human Genetics (ASHG) ...

Milestone highlights growing adoption of DNA and RNA-informed diagnostics for hereditary cancer and rare disease Ambry Genetics, a leader in clinical genomic testing, and now a wholly owned subsidiary ...

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Ambry Genetics, a leader in clinical genetic and genomic testing, today announced enhancements to their portfolio of tests for the detection of genetic mutations ...

Evanston, Ill.-based NorthShore University HealthSystem’s center for personalized medicine will partner with Aliso Viejo, Calif.-based Ambry Genetics to offer 10,000 patients genetic testing. Ambry ...

Gift Article 10 Remaining As a subscriber, you have 10 articles to gift each month. Gifting allows recipients to access the article for free. Tempus AI announced today it is acquiring genetic testing ...

Konica Minolta Inc., best known as a maker of printers and cameras, about a decade ago decided to pivot into the medical industry. Hence, in 2017, the Tokyo-based company bought Ambry Genetics, an ...

Tokyo, Japan-based Konica Minolta, a digital technology company, acquired Aliso Viejo, Calif.-based Ambry Genetics Corp., a genetic testing firm, to expand its precision medicine offerings. The Konica ...

CHICAGO--(BUSINESS WIRE)-- Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced it has completed its ...

Shares of Tempus AI TEM gained 18.4% after it announced an agreement, on Nov. 4, 2024, to acquire Ambry Genetics for $600 million. This acquisition will likely help Tempus revolutionize healthcare by ...

Peer-reviewed study in the Journal of the National Comprehensive Cancer Network describes the CARE program’s utility as digital risk assessment tool validated with real-world patient data ...

Milestone highlights growing adoption of DNA and RNA-informed diagnostics for hereditary cancer and rare disease ALISO VIEJO, Calif., February 02, 2026--(BUSINESS WIRE)--Ambry Genetics, a leader in ...